The U.S. company CardioFocus just won approval from the Food and Drug Administration for its HeartLightendoscopic cardiac ablation system for treating paroxysmal atrial fibrillation.
The HeartLight consists of a balloon catheter, a deflectable sheath introducer, an endoscope and an integrated console. The main advantage is that it provides direct visual observation of the area where tissue is to be removed. It differs from other solutions that rely on x-ray or mapping support by allowing the physician to deliver therapeutic laser energy under direct visual observation, a first.
Results from a trial on 353 participants showed that after a single ablation procedure using the HeartLight, the majority of patients were free of paroxysmal atrial fibrillation at 12 months.
Celia Sampol has been a journalist for more than 15 years. She worked in Brussels and Washington for national medias (Agence France Presse, Liberation, Europolitics). She's the editor-in-chief of NauticExpo e-magazine and MedicalExpo e-magazine.